The “Wegovy” brand slimming syringe is sold in the Achat pharmacy in Mitte. The “Wegovy” slimming syringe has been available in Germany for a year. Jens Kalaene | Picture Alliance | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. … Read more
A mural depicting Samsui women in Chinatown in Singapore. Edwin Koo | Getty Images From listening devices that detect falls to “patient sitter” systems in hospitals and robots helping with exercise in care homes, Singapore is looking to artificial intelligence to help manage the health of its elderly population. By 2030, a quarter of Singaporeans … Read more
The Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama | Getty Images Amgen on Wednesday said it has started two critical late-stage trials for its experimental weight loss injection MariTide, another step in its bid to enter the booming obesity drug market. “We’re delighted to share … Read more
A sign stands outside an Abbvie facility in Cambridge, Massachusetts. Brian Snyder | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The booming weight loss drug market has gained a new potential competitor. AbbVie … Read more
The U.S. Food and Drug Administration regulates food and health-related products to ensure they’re safe for public health. Today, it’s estimated to oversee 80% of the U.S. food supply. This also places ingredient safety regulations under the FDA’s authority. According to a 1958 law, companies looking to introduce a new food additive into the food … Read more
Dan Skovronsky knows what makes a good obesity drug. As chief scientific officer at Eli Lilly, he’s already done it once with the company’s weekly shot, Zepbound. He’s trying to do it again with a more convenient daily pill, then repeat the feat with a shot that could be even more powerful than Zepbound. And … Read more
Heart disease. Hearing loss. Addiction. Chronic pain. Alzheimer’s. ALS. These are some of the areas where Eli Lilly, flush with cash from its GLP-1 drugs, wants to make big bets. These are the ideas that are “hiding in plain sight,” said Lilly Chief Scientific Officer Dan Skovronsky. They’re places where other pharmaceutical companies might not … Read more
Steve Christo | Corbis News | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novo Nordisk‘s blockbuster diabetes drug Ozempic may also help people drink less alcohol. That’s according to new government-funded research … Read more